Regulatory Post Marketing Surveillance Study on YAZ

Inclusion criteria

• Healthy female subjects

• requesting contraception
• suggesting PMDD by Physician who are also requesting contraception
• with acne who are also requesting contraception
• Age: 18 - 50 years
• Women who is prescribed YAZ first, during study period

Exclusion criteria

• Women who are contraindicated based on the label of YAZ

• Presence or a history of venous or arterial thrombotic/ thromboembolic events (e.g. deep venous thrombosis, pulmonary embolism, myocardial infarction) or of a cerebrovascular accident
• Presence or history of prodromi of a thrombosis (e.g. transient ischaemic attack, angina pectoris)
• History of migraine with focal neurological symptoms
• Diabetes mellitus with vascular involvement
• The presence of a severe or multiple risk factor(s) for venous or arterial thrombosis may also constitute a contraindication
• Pancreatitis or a history thereof if associated with severe hypertriglyceridemia
• Presence or history of severe hepatic disease as long as liver function values have not returned to normal
• Severe renal insufficiency or acute renal failure
• Presence or history of liver tumours (benign or malignant)
• Known or suspected sex-steroid influenced malignancies (e.g. of the genital organs or the breasts)
• Undiagnosed vaginal bleeding
• Known or suspected pregnancy
• Hypersensitivity to the active substances or to any of the excipients